Rituximab-associated neutropenia

Seminars in Hematology

Volumn 47, Issue 2, 2010, Pages 180-186

  Dunleavy, Kieron ^a   Tay, Kevin ^a   Wilson, Wyndham H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; STROMAL CELL DERIVED FACTOR 1; VINCRISTINE; VINDESINE;

ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CELL DESTRUCTION; CHRONIC LYMPHATIC LEUKEMIA; DRUG MEGADOSE; ERYTHROCYTE APLASIA; FOLLICULAR LYMPHOMA; GRANULOCYTE; HEMATOLOGIC DISEASE; HOMEOSTASIS; HUMAN; INCIDENCE; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; NEUTROPENIA; PATHOGENESIS; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRHEUMATIC AGENTS; CHEMOKINE CXCL12; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTES; HOMEOSTASIS; HUMANS; INCIDENCE; LYMPHOMA, NON-HODGKIN; NEUTROPENIA; PREDNISONE; TIME FACTORS; VINCRISTINE;

EID: 77950314505     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.01.009     Document Type: Article

References (35)

1. Stashenko P., Nadler L.M., Hardy R., Schlossman S.F. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980, 125:1678-1685.
2. Bhan A.K., Nadler L.M., Stashenko P., McCluskey R.T., Schlossman S.F. Stages of B cell differentiation in human lymphoid tissue. J Exp Med 1981, 154:737-749.
3. Maloney D.G., Grillo-Lopez A.J., White C.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
4. Davis T.A., Grillo-Lopez A.J., White C.A., et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000, 18:3135-3143.
5. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
6. O'Brien S.M., Kantarjian H., Thomas D.A., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001, 19:2165-2170.
7. McDonald V., Leandro M. Rituximab in non-haematological disorders of adults and its mode of action. Br J Haematol 2009, 146:233-246.
8. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
9. Dunleavy K., Hakim F., Kim H.K., et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005, 106:795-802.
10. Tedder TF EP. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunology Today;15:540-4.
11. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
12. Papadaki T., Stamatopoulos K., Stavroyianni N., Paterakis G., Phisphis M., Stefanoudaki-Sofianatou K. Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: report of two cases. Leuk Res 2002, 26:597-600.
13. Voog E., Morschhauser F., Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003, 348:2691-2694.
14. Nitta E., Izutsu K., Sato T., et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 2007, 18:364-369.
15. Lai G.G., Lim S.T., Tao M., Chan A., Li H., Quek R. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol 2009, 84:414-417.
16. Lemieux B., Tartas S., Traulle C., et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004, 33:921-923.
17. Rios-Fernandez R., Gutierrez-Salmeron M.T., Callejas-Rubio J.L., Fernandez-Pugnaire M., Ortego-Centeno N. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br J Dermatol 2007, 157:1271-1273.
18. Cattaneo C., Spedini P., Casari S., et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006, 47:1013-1017.
19. Chaiwatanatorn K., Lee N., Grigg A., Filshie R., Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003, 121:913-918.
20. Papadaki T., Stamatopoulos K., Anagnostopoulos A., Fassas A. Rituximab-associated immune myelopathy. Blood 2003, 102:1557-1558.
21. Suratt B.T., Petty J.M., Young S.K., et al. Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil homeostasis. Blood 2004, 104:565-571.
22. Martin C., Burdon P.C., Bridger G., Gutierrez-Ramos J.C., Williams T.J., Rankin S.M. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 2003, 19:583-593.
23. Tokoyoda K., Egawa T., Sugiyama T., Choi B.I., Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004, 20:707-718.
24. Lapidot T., Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002, 30:973-981.
25. Ma Q., Jones D., Springer T.A. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999, 10:463-471.
26. Zou Y.R., Kottmann A.H., Kuroda M., Taniuchi I., Littman D.R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.
27. Egawa T., Kawabata K., Kawamoto H., et al. The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor. Immunity 2001, 15:323-334.
28. Ceradini D.J., Kulkarni A.R., Callaghan M.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004, 10:858-864.
29. Villalba S., Salvucci O., Aoki Y., et al. Serum inactivation contributes to the failure of stromal-derived factor-1 to block HIV-I infection in vivo. J Leukoc Biol 2003, 74:880-888.
30. Sei S., O'Neill D.P., Stewart S.K., et al. Increased level of stromal cell-derived factor-1 mRNA in peripheral blood mononuclear cells from children with AIDS-related lymphoma. Cancer Res 2001, 61:5028-5037.
31. Forster R., Kremmer E., Schubel A., et al. Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. J Immunol 1998, 160:1522-1531.
32. Rose M.G., Berliner N. T-cell large granular lymphocyte leukemia and related disorders. Oncologist 2004, 9:247-258.
33. Wong K.F., Chan J.C., Liu H.S., Man C., Kwong Y.L. Chromosomal abnormalities in T-cell large granular lymphocyte leukaemia: report of two cases and review of the literature. Br J Haematol 2002, 116:598-600.
34. Terrier B., Ittah M., Tourneur L., et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica 2007, 92:e20-e23.
35. Weng W., Negrin R.S., Lavori P., Horning S.J. Immunoglobulin G Fc receptor FcγRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2010, 28:279-284.